Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

British Journal of Cancer

Volumn 88, Issue 2, 2003, Pages 181-186

  Ray Coquard, I ^a   Borg, C ^a   Bachelot, Th ^a   Sebban, C ^a   Philip, I ^a   Clapisson, G ^a   Le Cesne, A ^b   Biron, P ^a   Chauvin, F ^a   Blay, J Y ^c,d  

^a Centre L Berard   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Febrile neutropenia; Lymphopenia; Risk factors; Risk model; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; COHORT STUDIES; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037468101     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600724     Document Type: Article

References (22)

1. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 17: 3676-3681
2. Blay JY, Borg C, Clapisson G, Philip I, Sebban C, Bachelot T, Caux C, Puisieux I, Biron P, Ray-Coquard I (2001) CD4+ and CD56+ lymphopenia (Lyp) as independent risk factors for febrile neutropenia (FN) in a HIV negative cancer patients treated with conventional chemotherapy (CT). Proc Am Soc Clin Oncol 20: 434a (abstract)
3. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14: 636-643
4. Blay JY, Fervers B, Latour JF, Philip T (1995) Standards, Options et Recommandations pour l'utilisation des facteurs de croissance hématopoïétiques en cancérologie. Bull Cancer 82(Suppl 4): 487s-508s
5. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, Sebban C, Guastalla J-P, Biron P, Ray-Coquard I, for the ELYPSE1 Study Group (1998) A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 92: 405-410
6. Bodey G (1986) Infection in cancer patients: a continuing association. Am J Med 8(Suppl 1A): 11-26
7. Bodey GP, Buckley M, Sathe YS et al (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Int Med 64: 328-340
8. Boogaerts M, Cavalli F, Cortes-Funes H, Gatell JM, Gianni AM, Khayat D, Levy Y, Link H (1995) Granulocyte growth factors: achieving a consensus. Ann Oncol 6: 237-244
9. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7: 1018-1026
10. Elias A, Ryan L, Sulkes A et al (1989) Response to mesna, doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7: 1208-1216
11. Klastersky J (1993) Febrile neutropenia. Curr Opin Oncol 5: 625-632
12. Miser JS, Kinsella TJ, Triche TJ et al (1987) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. I Clin Oncol 5: 1191-1198
13. Nichols C, Williams S, Loehrer PJ et al (1991) Randomised study of cisplatin dose intensity in poor risk germ cell tumors: a South Eastern Cancer study Group and South West Oncology Group Protocol. J Clin Oncol 9: 1163-1172
14. Pizzo PA, Hathorn JW, Hiemenz et al (1987) A randomised trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552-558
15. Ray-Coquard I, Ghesquiere H, Bachelot T, Borg C, Biron P, Sebban C, Le Cesne A, Chauvin F, Blay J-Y (2001) Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 85: 816-822
16. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY for the ELYPSE1 Study Group (1999) A risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 17: 2840-2846
17. Segal BH, Walsh TJ, Holland SM (2001) Infection in the cancer patient. In Cancer. Principles and Practice of Oncology, 6th edn. DeVita VT, Hellman S, Rosenberg SA (eds). pp 2815-2868. Philadelphia, PA: Lippincott
18. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective two-center validation of a prediction rule. J Clin Oncol 10: 316-322
19. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Laroque G et al (1988) A randomised trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387
20. The American Society of Clinical Oncology (1994) American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 12: 2471-2508
21. The International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 137: 14-29
22. Velasquez W, Cabanillas F, Salvador P et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 72: 117-122